CL2014002505A1 - Compuestos derivados de piridopirimidina substituida, como inhibidores de flt3; formulacion farmaceutica que los comprende; y su uso para el tratamiento de tumores hematologicos malignos tal como leucemias, enfermedades autoinmunes y tumores solidos malignos. - Google Patents
Compuestos derivados de piridopirimidina substituida, como inhibidores de flt3; formulacion farmaceutica que los comprende; y su uso para el tratamiento de tumores hematologicos malignos tal como leucemias, enfermedades autoinmunes y tumores solidos malignos.Info
- Publication number
- CL2014002505A1 CL2014002505A1 CL2014002505A CL2014002505A CL2014002505A1 CL 2014002505 A1 CL2014002505 A1 CL 2014002505A1 CL 2014002505 A CL2014002505 A CL 2014002505A CL 2014002505 A CL2014002505 A CL 2014002505A CL 2014002505 A1 CL2014002505 A1 CL 2014002505A1
- Authority
- CL
- Chile
- Prior art keywords
- malignant
- tumors
- flt3
- leukemia
- inhibitors
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000005787 hematologic cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000032839 leukemia Diseases 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000008518 pyridopyrimidines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614274P | 2012-03-22 | 2012-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002505A1 true CL2014002505A1 (es) | 2015-10-02 |
Family
ID=49223277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002505A CL2014002505A1 (es) | 2012-03-22 | 2014-09-22 | Compuestos derivados de piridopirimidina substituida, como inhibidores de flt3; formulacion farmaceutica que los comprende; y su uso para el tratamiento de tumores hematologicos malignos tal como leucemias, enfermedades autoinmunes y tumores solidos malignos. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8877763B2 (es) |
| EP (1) | EP2828259B1 (es) |
| JP (1) | JP6101341B2 (es) |
| KR (1) | KR102011770B1 (es) |
| CN (1) | CN104428298B (es) |
| AU (1) | AU2013235344B2 (es) |
| BR (1) | BR112014023460B1 (es) |
| CA (1) | CA2868156C (es) |
| CL (1) | CL2014002505A1 (es) |
| EA (1) | EA031267B1 (es) |
| ES (1) | ES2694223T3 (es) |
| IL (1) | IL234802B (es) |
| IN (1) | IN2014MN02082A (es) |
| MX (1) | MX360912B (es) |
| MY (1) | MY184858A (es) |
| NZ (1) | NZ700283A (es) |
| PL (1) | PL2828259T3 (es) |
| SG (1) | SG11201405942RA (es) |
| TR (1) | TR201816480T4 (es) |
| WO (1) | WO2013142382A1 (es) |
| ZA (1) | ZA201407588B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3060562T3 (pl) * | 2013-10-21 | 2022-01-10 | Genosco | Podstawione związki pirymidynowe i ich zastosowanie jako inhibitory syk |
| CN105272930B (zh) * | 2014-07-17 | 2018-07-13 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
| KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
| JP6836989B2 (ja) | 2014-11-17 | 2021-03-03 | ロード アイランド ホスピタル | ナノ材料組成物、合成方法、およびアセンブリ |
| US12350272B2 (en) * | 2018-06-27 | 2025-07-08 | Oscotec Inc. | Pyridopyrimidinone derivatives for use as AXL inhibitors |
| KR20200022712A (ko) * | 2018-08-23 | 2020-03-04 | 주식회사 오스코텍 | 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법 |
| KR102230721B1 (ko) | 2019-02-01 | 2021-03-22 | 주식회사 오스코텍 | 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN110327347B (zh) * | 2019-08-16 | 2021-06-01 | 陕西科技大学 | G-749在制备抗真菌药物中的应用 |
| TWI759829B (zh) * | 2019-08-23 | 2022-04-01 | 財團法人生物技術開發中心 | 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物 |
| AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| KR20240128987A (ko) | 2021-12-30 | 2024-08-27 | 바이오메아 퓨전, 인크. | Flt3의 억제제로서의 피라진 화합물 |
| WO2023225005A1 (en) | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
| KR102440707B1 (ko) | 2022-07-10 | 2022-09-05 | 이우미 | 공장 추천 시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20022521A3 (cs) * | 2000-01-27 | 2003-02-12 | Warner-Lambert Company | Pyridopyrimidinonové deriváty pro léčení neurodegenerativních onemocnění |
| JP4146721B2 (ja) * | 2000-08-31 | 2008-09-10 | エフ．ホフマン−ラ ロシュ アーゲー | ７−オキソ−ピリドピリミジン類 |
| JP4141830B2 (ja) * | 2000-08-31 | 2008-08-27 | エフ．ホフマン−ラ ロシュ アーゲー | 細胞増殖の阻害剤としての７−オキソ−ピリドピリミジン類 |
| EP2025678A1 (en) * | 2007-08-17 | 2009-02-18 | Oncalis AG | Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| US8383635B2 (en) * | 2008-08-12 | 2013-02-26 | Glaxosmithkline Llc | Chemical compounds |
| US8338481B2 (en) * | 2009-01-28 | 2012-12-25 | Ramot At Tel-Aviv University Ltd. | Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer |
| EP2467137A1 (en) * | 2009-08-19 | 2012-06-27 | Ambit Biosciences Corporation | Biaryl compounds and methods of use thereof |
| EP2493313B1 (en) * | 2009-10-29 | 2017-12-13 | Genosco | Kinase inhibitors |
-
2013
- 2013-03-15 JP JP2015501823A patent/JP6101341B2/ja active Active
- 2013-03-15 MY MYPI2014702705A patent/MY184858A/en unknown
- 2013-03-15 EP EP13763998.5A patent/EP2828259B1/en active Active
- 2013-03-15 MX MX2014011354A patent/MX360912B/es active IP Right Grant
- 2013-03-15 PL PL13763998T patent/PL2828259T3/pl unknown
- 2013-03-15 AU AU2013235344A patent/AU2013235344B2/en active Active
- 2013-03-15 CN CN201380025782.8A patent/CN104428298B/zh active Active
- 2013-03-15 WO PCT/US2013/032575 patent/WO2013142382A1/en active Application Filing
- 2013-03-15 BR BR112014023460-4A patent/BR112014023460B1/pt active IP Right Grant
- 2013-03-15 KR KR1020147029509A patent/KR102011770B1/ko active Active
- 2013-03-15 IN IN2082MUN2014 patent/IN2014MN02082A/en unknown
- 2013-03-15 EA EA201491747A patent/EA031267B1/ru not_active IP Right Cessation
- 2013-03-15 US US13/841,827 patent/US8877763B2/en active Active
- 2013-03-15 SG SG11201405942RA patent/SG11201405942RA/en unknown
- 2013-03-15 ES ES13763998.5T patent/ES2694223T3/es active Active
- 2013-03-15 TR TR2018/16480T patent/TR201816480T4/tr unknown
- 2013-03-15 CA CA2868156A patent/CA2868156C/en active Active
- 2013-03-15 NZ NZ700283A patent/NZ700283A/en unknown
-
2014
- 2014-09-22 IL IL234802A patent/IL234802B/en active IP Right Grant
- 2014-09-22 CL CL2014002505A patent/CL2014002505A1/es unknown
- 2014-10-20 ZA ZA2014/07588A patent/ZA201407588B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201405942RA (en) | 2014-10-30 |
| JP2015510942A (ja) | 2015-04-13 |
| EP2828259A1 (en) | 2015-01-28 |
| CA2868156C (en) | 2020-07-28 |
| MX2014011354A (es) | 2014-12-05 |
| EA201491747A1 (ru) | 2015-10-30 |
| NZ700283A (en) | 2016-08-26 |
| BR112014023460B1 (pt) | 2020-09-01 |
| MX360912B (es) | 2018-11-22 |
| AU2013235344A1 (en) | 2014-10-09 |
| CN104428298A (zh) | 2015-03-18 |
| JP6101341B2 (ja) | 2017-03-22 |
| HK1208453A1 (en) | 2016-03-04 |
| AU2013235344B2 (en) | 2017-03-16 |
| EA031267B1 (ru) | 2018-12-28 |
| CN104428298B (zh) | 2017-03-01 |
| EP2828259A4 (en) | 2015-08-19 |
| IN2014MN02082A (es) | 2015-08-21 |
| TR201816480T4 (tr) | 2018-11-21 |
| CA2868156A1 (en) | 2013-09-26 |
| EP2828259B1 (en) | 2018-08-08 |
| MY184858A (en) | 2021-04-27 |
| US8877763B2 (en) | 2014-11-04 |
| WO2013142382A1 (en) | 2013-09-26 |
| US20130274274A1 (en) | 2013-10-17 |
| KR20140144709A (ko) | 2014-12-19 |
| ES2694223T3 (es) | 2018-12-19 |
| PL2828259T3 (pl) | 2019-02-28 |
| IL234802B (en) | 2018-10-31 |
| ZA201407588B (en) | 2015-11-25 |
| KR102011770B1 (ko) | 2019-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014002505A1 (es) | Compuestos derivados de piridopirimidina substituida, como inhibidores de flt3; formulacion farmaceutica que los comprende; y su uso para el tratamiento de tumores hematologicos malignos tal como leucemias, enfermedades autoinmunes y tumores solidos malignos. | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| CL2015001733A1 (es) | Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer. | |
| CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CL2014002412A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras. | |
| CL2014002301A1 (es) | Compuestos derivados de pirimidin piridinas sustituidas, inhibidores de serina/treonina cinasas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento de una enfermedad hiperproliferativa tal como melanoma, cancer, leucemias y una enfermedad inflamatoria como artritis y reumatismo entre otras. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2016002877A1 (es) | Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos. | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
| CL2016000922A1 (es) | Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4 | |
| CL2015001377A1 (es) | Inhbibidores de bmi-1 primidinas sustituidas inversas | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| CL2015003280A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| CL2015002394A1 (es) | Inhibidores de histona desmetilasas | |
| MX380829B (es) | Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa. | |
| CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CL2012002270A1 (es) | Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer. | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| CL2016001895A1 (es) | Compuestos | |
| CL2014001103A1 (es) | Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros. | |
| CL2014001065A1 (es) | Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer. | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. |